寻找非 G12C-KRAS 突变型癌症的治疗方法。
Searching for treatments for non-G12C-KRAS mutant cancers.
机构信息
The Institute of Cancer Research, London, UK.
The Royal Marsden Hospital NHS Foundation Trust, London, UK.
出版信息
Br J Cancer. 2021 Aug;125(5):625-626. doi: 10.1038/s41416-021-01357-2. Epub 2021 Apr 15.
Abstract
KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF-MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers.
摘要
KRAS 突变驱动着多种癌症。目前正在评估针对 KRAS 突变蛋白产物的药物，这些药物在临床试验中显示出初步疗效。一项针对双重 RAF-MEK 抑制剂 VS-6766 的临床试验报告称，在非 G12C 突变驱动的 KRAS 驱动的癌症中，该药物具有早期单药活性。
Zotero 插件